Canagliflozine (French Wikipedia)

Analysis of information sources in references of the Wikipedia article "Canagliflozine" in French language version.

refsWebsite

Global rank French rank

2nejm.org

2,374^th place

298^th place

1qmul.ac.uk

1,735^th place

168^th place

1acs.org

1,248^th place

778^th place

1europa.eu

68^th place

67^th place

1plosone.org

4,730^th place

1,427^th place

1wiley.com

222^nd place

129^th place

1thelancet.com

2,393^rd place

506^th place

1ahajournals.org

3,608^th place

659^th place

1sante.fr

8,603^rd place

517^th place

acs.org

pubs.acs.org

Nomura S, Sakamaki S, Hongu M et al. Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus, J Med Chem, 2010;53:6355-6360

ahajournals.org

Rådholm K, Figtree G, Perkovic V et al. Canagliflozin and heart failure in type 2 diabetes mellitus, results from the CANVAS program, Circulation, 2018;138:458-468

europa.eu

ema.europa.eu

« Invokana - European Medicines Agency », sur European Medicines Agency, 17 septembre 2018 (consulté le 28 août 2020).

nejm.org

Neal B, Perkovic V, Mahaffey KW et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes, N Engl J Med, 2017;377:644-657
Perkovic V, Jardine MJ, Neal B et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy, N Engl J Med, 2019;380:2295-2306

plosone.org

Liang Y, Arakawa K, Ueta K et al. Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models, PLoS One, 2012;7:e30555

qmul.ac.uk

chem.qmul.ac.uk

Masse molaire calculée d’après « Atomic weights of the elements 2007 », sur www.chem.qmul.ac.uk.

sante.fr

ansm.sante.fr

Actualité de l'Agence National de Sécurité du Médicament

thelancet.com

Cefalu WT, Leiter LA, Yoon K-H et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial, Lancet, 2013;382:941-950

wiley.com

onlinelibrary.wiley.com

Devineni D, Morrow L, Hompesch M et al. Canagliflozin improves glycemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin, Diabetes Obes Metab, 2012;14:539-545